Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate. Transfus Med Rev 2016 10;30(4):189-96

Date

09/01/2016

Pubmed ID

27576087

DOI

10.1016/j.tmrv.2016.07.002

Scopus ID

2-s2.0-84994876768   3 Citations

Abstract

Although congenital bleeding disorders can manifest in the newborn period, the most common causes of bleeding and thrombosis in neonates are acquired conditions. Factor concentrates are used for specific diagnoses (hemophilia with inhibitors, specific factor deficiency, von Willebrand disease) and approved indications, and increasingly for off-label indications (bleeding in surgery cardiopulmonary bypass, extracorporeal membrane oxygenation). We will review the approved indications for factor products in the neonate and discuss the evidence and rationale for off-label use of factor products in management of bleeding and thrombosis in the neonate.

Author List

Punzalan RC, Gottschall JL

Author

Rowena C. Punzalan MD Associate Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Anticoagulants
Blood Coagulation
Factor VIII
Factor VIIa
Hematology
Hemophilia A
Hemorrhage
Humans
Infant, Newborn
Infant, Premature
Recombinant Proteins
Thrombosis
von Willebrand Diseases
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a